Teva Braces For A Bigger Hit As Price Competition Intensifies For Copaxone
Teva has been able to hold onto a roughly 85% share of the Copaxone 40 mg market, but expects pressure from generics will intensify in the second half of the year.
Teva has been able to hold onto a roughly 85% share of the Copaxone 40 mg market, but expects pressure from generics will intensify in the second half of the year.